Adverum Biotechnologies

Adverum Biotechnologies is a gene therapy company committed to discovering and developing novel medicines that can offer life-changing therapeutic benefit to patients dealing with chronic or debilitating disease. The company is leveraging its next generation adeno-associated virus (AAV)-based directed evolution platform to generate product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.
Company Growth (employees)
Type
Public
HQ
Menlo Park, US
Founded
2006
Size (employees)
61 (est)
Adverum Biotechnologies was founded in 2006 and is headquartered in Menlo Park, US

Key People at Adverum Biotechnologies

Amber Salzman

Amber Salzman

CEO / President
Leone Patterson

Leone Patterson

CFO
Mehdi Gasmi

Mehdi Gasmi

CTO

Adverum Biotechnologies Office Locations

Adverum Biotechnologies has offices in Menlo Park and Philadelphia
Menlo Park, US (HQ)
1035 O'Brien Dr

Adverum Biotechnologies Data and Metrics

Adverum Biotechnologies Financial Metrics

Adverum Biotechnologies's revenue was reported to be $1.5 m in FY, 2016
USD

Net income (Q1, 2017)

(16.1 m)

EBIT (Q1, 2017)

(16.6 m)

Market capitalization (20-Jul-2017)

113.6 m

Closing share price (20-Jul-2017)

2.7

Cash (31-Mar-2017)

71.6 m
Adverum Biotechnologies's current market capitalization is $113.6 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

572 k2.3 m1.5 m

Revenue growth, %

305%(37%)

R&D expense

17 m25.5 m31.7 m

General and administrative expense

8 m22.1 m24.4 m

Operating expense total

25 m50.1 m116.7 m

EBIT

(24.4 m)(47.8 m)(115.3 m)

EBIT margin, %

(4266%)(2062%)(7923%)

Interest expense

(18 k)(18 k)(18 k)

Income tax expense

775 k

Net Income

(25.4 m)(47.5 m)(113.7 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

135 k204 k

R&D expense

3.1 m5.7 m5.6 m5.1 m7.5 m7.5 m8 m8.4 m9.1 m

General and administrative expense

1.5 m2.4 m4.1 m5 m7.6 m8.3 m5.1 m6.1 m8 m

Operating expense total

4.6 m8.1 m9.8 m10.1 m15.2 m15.8 m13.1 m14.5 m17.1 m

EBIT

(4.5 m)(7.9 m)(9.6 m)(9.9 m)(14.2 m)(15.5 m)(61.9 m)(14.5 m)(16.6 m)

EBIT margin, %

(3299%)(3892%)

Interest expense

(4 k)(14 k)(4 k)

Net Income

(5.1 m)(8.3 m)(9.5 m)(9.8 m)(14.1 m)(15.4 m)(61.7 m)(14.3 m)(16.1 m)
USDFY, 2014FY, 2015FY, 2016

Cash

159.4 m221.3 m222.2 m

Inventories

874 k1.5 m2.2 m

Current Assets

160.3 m261 m225.3 m

PP&E

1.1 m3.2 m4.2 m

Total Assets

161.9 m264.3 m234.6 m

Accounts Payable

951 k605 k1.5 m

Current Liabilities

5.5 m6.6 m9.9 m

Total Liabilities

19 m

Additional Paid-in Capital

186.2 m336.8 m413.5 m

Retained Earnings

(36.7 m)(84.2 m)(197.9 m)

Total Equity

149.5 m252.6 m215.6 m

Financial Leverage

1.1 x1 x1.1 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

52.4 m165.3 m201.8 m200.5 m200.7 m247.1 m241.3 m231.3 m71.6 m

Accounts Receivable

8 k8 k

Current Assets

52.9 m166.3 m291.1 m280.6 m270.4 m249.2 m243.6 m235.9 m212.6 m

PP&E

509 k817 k1.4 m2.9 m3.3 m3.6 m4 m4.3 m4.1 m

Total Assets

54.8 m167.2 m292.7 m283.7 m273.8 m252.9 m264.3 m256.6 m221.9 m

Accounts Payable

1.6 m1.6 m2.8 m1.9 m1.1 m486 k2.4 m3.1 m3.4 m

Current Liabilities

4 m4.5 m7.6 m7.9 m6.5 m5.6 m7.9 m10.6 m12 m

Additional Paid-in Capital

1.5 m182 m325.9 m326.6 m332.4 m341.1 m408.9 m411.8 m415.6 m

Retained Earnings

(18.1 m)(26.3 m)(46.2 m)(56 m)(70.1 m)(99.6 m)(161.2 m)(175.5 m)(214 m)

Total Equity

(16.5 m)155.7 m279.7 m270.6 m262.3 m241.6 m247.7 m236.2 m201.4 m

Financial Leverage

-3.3 x1.1 x1 x1 x1 x1 x1.1 x1.1 x1.1 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(25.4 m)(47.5 m)(113.7 m)

Depreciation and Amortization

162 k812 k1.6 m

Accounts Receivable

8 k(44 k)(437 k)

Inventories

(624 k)(531 k)71 k

Accounts Payable

(6 k)18.2 m(111 k)

Cash From Operating Activities

(5.6 m)(35.3 m)(38.4 m)

Purchases of PP&E

(943 k)(3 m)(2.4 m)

Cash From Investing Activities

(943 k)(41.6 m)38.8 m

Cash From Financing Activities

165.4 m138.9 m556 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(5.1 m)(8.3 m)(9.5 m)(9.8 m)(14.1 m)(15.4 m)(61.7 m)(14.3 m)(16.1 m)

Accounts Receivable

8 k8 k

Accounts Payable

1.6 m1.6 m2.8 m1.9 m1.1 m486 k2.4 m3.1 m3.4 m
Y, 2017

Financial Leverage

1.1 x

Adverum Biotechnologies Operating Metrics

FY, 2016

Patents Pending

60

Patents Issued

12

Adverum Biotechnologies Market Value History

Adverum Biotechnologies Job Categories

Traffic Overview of Adverum Biotechnologies

Adverum Biotechnologies Online and Social Media Presence

Adverum Biotechnologies Company Life and Culture

You may also be interested in